Tesamorelin vs Sermorelin: Overview
Tesamorelin and sermorelin are both growth-hormone-releasing hormone (GHRH) analogs, which places them in the same receptor family and makes their comparison one of structure and stability rather than mechanism class. Both engage the GHRH receptor on the anterior pituitary, but they differ in how the peptide backbone is constructed and protected.
Sermorelin corresponds to GHRH (1-29), the shortest fragment of endogenous GHRH that retains full receptor-activating capacity in research models. Tesamorelin is also based on the GHRH (1-44) framework but carries a stabilizing acyl (trans-3-hexenoyl) modification at its N-terminus. This acylation is the defining structural distinction and is understood in the literature to improve the molecule’s resistance to enzymatic degradation.
This comparison examines Tesamorelin (10mg) and Sermorelin (10mg) at the level of sequence, modification, and research application only. For research use only; not for human or animal consumption.
Recommended Products
Structure, Stability and Mechanism
Because both peptides target the same GHRH receptor, researchers studying the two typically focus on how structural modification alters stability and comparative potency in controlled assays. Sermorelin is an unmodified 29-residue fragment. Tesamorelin adds a fatty-acid moiety and a longer backbone, changes intended in the research literature to reduce susceptibility to dipeptidyl peptidase and other proteases.
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog (stabilized) |
| Sequence basis | GHRH (1-29) | GHRH (1-44) framework |
| Modification | None (native fragment) | N-terminal acylation |
| Receptor target | GHRH receptor | GHRH receptor |
| Stability note | Shorter, unprotected | Reported enhanced protease resistance |
The practical upshot for research design is that these two compounds let investigators isolate the effect of structural stabilization while holding the receptor target constant. A study comparing native versus acylated GHRH analogs would use sermorelin as the baseline and tesamorelin as the modified reference. Investigators exploring the broader secretagogue landscape often also include a GHRP such as Ipamorelin (10mg), which targets the separate ghrelin receptor, to contrast the two receptor systems. Because tesamorelin’s acyl group changes its physicochemical profile, its solubility and handling characteristics differ from the smaller sermorelin peptide and should be assessed separately. For context on how GHRH analogs sit alongside other secretagogue classes, see the pillar overview on growth hormone secretagogues compared.
How Researchers Choose These
Selection between tesamorelin and sermorelin generally reflects the research question about structural stability. When the goal is to model near-native GHRH-receptor engagement, sermorelin is the common reference. When the objective involves studying the effect of acylation and enzymatic resistance on a GHRH analog, tesamorelin provides the modified counterpart. Comparative designs use both to hold the receptor constant while varying only structure.
Handling of these peptides follows standard laboratory practice for lyophilized material: reconstitution with an appropriate sterile diluent, cold storage, protection from light, and minimized freeze-thaw cycling. Note that tesamorelin’s larger, acylated structure gives it a different molecular weight and solubility behavior than sermorelin, so reconstitution volumes and diluent choices should be calculated per compound. Document lot numbers and preparation details to support reproducibility. Review Tesamorelin (10mg) and Sermorelin (10mg) specifications before designing a comparative study. For research use only.